Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Will Manufacture siRNAs for Calando

NEW YORK (GenomeWeb News) - Agilent Technologies will manufacture siRNAs for Calando, Calando said today.
 
Agilent will manufacture the active siRNA component for Calando’s targeted siRNA anti-cancer therapeutic, CALAA01. Agilent will also provide Investigational New Drug-enabling services such as pharmacokinetic and toxicity studies and cGMP production.
 
Calando is a majority owned subsidiary of Arrowhead Research Formed. Founded in 2005, it creates, develops and sells technologies for the therapeutic use of RNAi.
 
Financial details of the agreement were not disclosed.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.